Maxcyte, INC. (MXCT) — SEC Filings

Overview

Maxcyte, INC. (MXCT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: MaxCyte, Inc. reported a significant decline in revenue and an increased net loss for the three and nine months ended September 30, 2025. Revenue for the three months decreased to $6.829 million from $8.164 million in the prior year, a 16.4% drop. For the nine months, revenue fell to $25.726 million

Sentiment Summary

Across 37 filings, the sentiment breakdown is: 2 bearish, 35 neutral. The dominant filing sentiment for Maxcyte, INC. is neutral.

Filing Type Overview

Maxcyte, INC. (MXCT) has filed 4 10-Q, 18 8-K, 1 DEFA14A, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (37)

• MaxCyte Revenue Plunges 16% Amid Widening Losses, Cash Burn Accelerates — 10-Q · Nov 13, 2025 Risk: high
  MaxCyte, Inc. reported a significant decline in revenue and an increased net loss for the three and nine months ended September 30, 2025. Revenue for the three
• 8-K Filing — 8-K · Nov 12, 2025
• MaxCyte, Inc. Files 8-K on Financials — 8-K · Nov 5, 2025 Risk: low
  MaxCyte, Inc. filed an 8-K on November 5, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements an
• MaxCyte Files 8-K on Exit Costs and Disclosures — 8-K · Sep 22, 2025 Risk: medium
  MaxCyte, Inc. filed an 8-K on September 22, 2025, reporting on cost associated with exit or disposal activities, Regulation FD disclosure, and financial stateme
• MaxCyte, Inc. Reports Leadership Changes and Compensation Details — 8-K · Aug 11, 2025 Risk: medium
  MaxCyte, Inc. filed an 8-K on August 11, 2025, reporting on the departure of directors or certain officers, the election of directors, and the appointment of ce
• MaxCyte's Q2 Loss Widens Amidst Revenue Dip — 10-Q · Aug 6, 2025 Risk: high
  MAXCYTE, INC. reported a net loss of $17.2 million for the three months ended June 30, 2025, a significant increase from the $14.5 million net loss in the prior
• MaxCyte, Inc. Files 8-K Report — 8-K · Jun 25, 2025 Risk: low
  On June 25, 2025, MaxCyte, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or
• MaxCyte Licenses Flow Electroporation Tech to Pharma Giant — 8-K · Jun 18, 2025 Risk: medium
  MaxCyte, Inc. announced on June 18, 2025, that it has entered into a collaboration and license agreement with a leading global pharmaceutical company. This agre
• MaxCyte Files 2025 Proxy Statement — DEFA14A · May 29, 2025 Risk: low
  MaxCyte, Inc. filed its Definitive Proxy Statement (DEFA14A) on May 29, 2025, for its 2025 Annual Meeting of Stockholders. The filing details the company's gove
• MaxCyte, Inc. Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: low
  MaxCyte, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information, including common stock and retained earnings as of
• MaxCyte Files 8-K on Operations and Financials — 8-K · May 7, 2025 Risk: low
  MaxCyte, Inc. filed an 8-K on May 7, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures an
• MaxCyte Files Definitive Proxy Statement for 2025 Shareholder Meeting — DEF 14A · Apr 28, 2025 Risk: low
  MaxCyte, Inc. filed its definitive proxy statement (DEF 14A) on April 28, 2025, for its annual meeting of stockholders. The filing outlines the proposals to be
• MaxCyte, Inc. Files 2024 10-K — 10-K · Mar 11, 2025 Risk: medium
  MaxCyte, Inc. filed its 2024 10-K on March 11, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The filing details the co
• MaxCyte, Inc. Files 8-K for Financials and Reg FD — 8-K · Jan 30, 2025 Risk: low
  MaxCyte, Inc. filed an 8-K on January 30, 2025, to report on financial statements and exhibits, as well as a Regulation FD disclosure. The filing does not conta
• MaxCyte, Inc. Files 8-K on Financials — 8-K · Jan 13, 2025 Risk: low
  MaxCyte, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements an
• MaxCyte Appoints New Chief Medical Officer — 8-K · Dec 27, 2024 Risk: low
  MaxCyte, Inc. announced on December 22, 2024, the appointment of Dr. David L. Davenport as Chief Medical Officer. Dr. Davenport brings extensive experience in c
• MaxCyte, Inc. Files 8-K on Exit Costs — 8-K · Dec 9, 2024 Risk: medium
  On December 4, 2024, MaxCyte, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing also includes Regulation FD Disclo
• SC 13G/A Filing — SC 13G/A · Nov 13, 2024
• SC 13G/A Filing — SC 13G/A · Nov 8, 2024
• MaxCyte, Inc. Files 8-K on Financials — 8-K · Nov 6, 2024 Risk: low
  MaxCyte, Inc. filed an 8-K on November 6, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosur
• SC 13G/A Filing — SC 13G/A · Oct 31, 2024
• SC 13G/A Filing — SC 13G/A · Oct 21, 2024
• MaxCyte Appoints New Chief Medical Officer — 8-K · Oct 15, 2024 Risk: medium
  MaxCyte, Inc. announced on October 14, 2024, the appointment of Dr. Aris D. T. K. K. Patel as Chief Medical Officer. Dr. Patel brings extensive experience in cl
• MaxCyte, Inc. Files Q2 2024 10-Q Report — 10-Q · Aug 6, 2024 Risk: medium
  MaxCyte, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations. Ke
• MaxCyte Elects New Directors, Stockholder Proposals Approved — 8-K · Jun 12, 2024 Risk: low
  MaxCyte, Inc. announced on June 11, 2024, the election of Dr. David L. Brown and Ms. Jennifer L. D. Sim as Class II directors to its Board of Directors, effecti
• MaxCyte, Inc. Files 8-K on Financials — 8-K · May 7, 2024 Risk: low
  MaxCyte, Inc. filed an 8-K on May 7, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures an
• MaxCyte, Inc. Announces 2024 Annual Meeting of Stockholders on June 11 — DEF 14A · Apr 26, 2024 Risk: low
  MAXCYTE, INC. (MXCT) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. MaxCyte, Inc. will hold its 2024 Annual Meeting of Stockholders on June 1
• SC 13G Filing — SC 13G · Mar 25, 2024
• MaxCyte, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 12, 2024 Risk:
  MAXCYTE, INC. (MXCT) filed a Annual Report (10-K) with the SEC on March 12, 2024. MaxCyte, Inc. filed its 2023 Form 10-K on March 12, 2024. The filing covers th
• MaxCyte Files 8-K on Operations and Financials — 8-K · Mar 5, 2024 Risk: low
  MaxCyte, Inc. filed an 8-K on March 5, 2024, reporting on its results of operations and financial condition as of March 4, 2024. The filing includes financial s
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 13, 2024
• Millennium's Integrated Core Strategies Files Amended 13G/A on MAXCYTE — SC 13G/A · Feb 1, 2024
  Integrated Core Strategies (US) LLC, part of Millennium Management LLC, filed an amended SC 13G/A on February 1, 2024, disclosing their ownership of MAXCYTE, IN
• BlackRock Amends MAXCYTE Stake Filing as of Dec 31, 2023 — SC 13G/A · Jan 26, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating its ownership of MAXCYTE, INC. Common Stock as of December 31, 2023. This filing update
• MAXCYTE 8-K: Officer/Director Changes & Comp Arrangements — 8-K · Jan 26, 2024
  MAXCYTE, INC. filed an 8-K on January 26, 2024, reporting an event that occurred on January 23, 2024, related to changes in directors or officers and their comp
• MAXCYTE Files 8-K on Financial Condition & Operations — 8-K · Jan 8, 2024
  MAXCYTE, INC. filed an 8-K on January 8, 2024, to report on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'. This filing

Risk Profile

Risk Assessment: Of MXCT's 23 recent filings, 2 were flagged as high-risk, 7 as medium-risk, and 14 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Maxcyte, INC.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: $6.829M
• Net Income: ($12.416M)
• EPS: ($0.33)
• Debt-to-Equity: 0.18
• Cash Position: $12.973M
• Operating Margin: -207.1%
• Total Assets: $213.476M
• Total Debt: $33.201M

Key Executives

• Dr. David L. Davenport
• Dr. Aris D. T. K. K. Patel
• Dr. David L. Brown
• Ms. Jennifer L. D. Sim
• Will Brooke
• John Johnston
• Richard Douglas

Industry Context

MaxCyte operates in the biotechnology tools and services sector, focusing on cell engineering technologies. The industry is characterized by rapid innovation, significant R&D investment, and a long product development cycle. Companies often rely on strategic partnerships and acquisitions to expand their platforms and market reach. Intense competition and the need for regulatory approvals are common.

Top Tags

financials (10) · Biotechnology (3) · disclosure (3) · annual-meeting (3) · governance (3) · Cell Therapy (2) · restructuring (2) · compensation (2) · proxy-statement (2) · 10-Q (2)

Key Numbers

• Revenue (3 months): $6.829M — Decreased from $8.164M in Q3 2024, a 16.4% decline.
• Revenue (9 months): $25.726M — Decreased from $29.934M in the prior year, a 14.0% decline.
• Net Loss (3 months): ($12.416M) — Widened from ($11.557M) in Q3 2024.
• Net Loss (9 months): ($35.034M) — Increased from ($30.458M) in the prior year.
• Cash and Cash Equivalents: $12.973M — Down from $27.884M at Dec 31, 2024, a 53.5% decrease.
• Restructuring Expense: $3.058M — New expense incurred during the three and nine months ended September 30, 2025.
• Goodwill: $3.554M — Added due to the acquisition of SeQure Dx Inc.
• Basic and Diluted Net Loss Per Share (9 months): ($0.33) — Increased from ($0.29) in the prior year.
• Common Stock Shares Outstanding: 106,644,343 — As of September 30, 2025.
• Accounts Receivable Concentration: 51% — One customer accounted for 51% of accounts receivable as of September 30, 2025.
• SEC File Number: 001-40674 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 52-2210438 — Company's tax identification number.
• Net Loss (Q2 2025): $17.2M — Increased from $14.5M in Q2 2024, indicating widening losses.
• Revenue (Q2 2025): $9.8M — Decreased by 6.7% from $10.5M in Q2 2024, showing revenue decline.
• Q2 Revenue Change: -6.7% — Percentage decrease in revenue from Q2 2024 to Q2 2025.

Frequently Asked Questions